

How to participate in the shareholder meeting?

Ordinary and Extraordinary Shareholder Meeting – June 24, 2026

Vote and give proxy to the Chairman via the Internet platform Votaccess

From June 3, 2026 at 9 am to June 23, 2026 at 3 pm

Registered shareholder*



Log in to the secure website <https://www.actionnaire.cic-marketsolutions.eu> using your credentials if your shares are held in pure registered form, or with the temporary codes received from CIC if your shares are held in administered registered form.



From the homepage, click on « **Vote or participate in the General Meeting** ».



You will then be automatically redirected to the VOTACCESS voting platform.

Bearer shareholder*



Log onto the web portal of your bank or broker, with your usual username and password.



Click on the icon displayed on the line corresponding to your **Nicox** shares or in the **General Meeting** section

You will only be able to vote online if your bank or broker is a member of the VOTACCESS system.

* See page 2 for the difference between registered and bearer shares

Attend the shareholder meeting in person

Request your admission card

By following the same procedure, you can request your **admission card**.

Vote by mail by using the proxy form

Proxy form to be received by CIC before June 21, 2026

If your shares are in **REGISTERED** form, please fill in the proxy form as explained below and send it back in the prepaid return envelope attached with your personal notice of convening.

If your shares are in **BEARER** form, please fill in the proxy form as explained below and send it back to your bank or financial institution holding your shares who will return it, with a **share certificate** to CIC Service Assemblées – 6 avenue de Provence - 75452 PARIS Cedex 09 – **your proxy form will not be accepted without this certificate**.

To attend the meeting in person
Tick this box

To vote by correspondence
Tick this box, then vote as per the instructions

To give proxy to the chairman
Tick this box

To give proxy to any other person or legal entity
Tick this box AND complete the required information

Add your name and address or check that they are correct if they are already registered

DATE and SIGN here

nicox
visible science

ORDINARY AND EXTRAORDINARY GENERAL MEETING
on Wednesday 24th June 2026 at 2.30 pm

Identifiant - Account
Nominatif Registered
Porteur Bearer
Vote simple Single vote
Vote double Double vote
Nombre de voix - Number of voting rights

JE VOTE PAR CORRESPONDANCE // I VOTE BY POST
Cf. au verso (2) - See reverse (2)

Sur les projets de résolutions non agréés, je vote en notifiant le cas échéant mon choix.
On the draft resolutions not approved, I cast my vote by shading the box of my choice.

JE DONNE POUVOIR AU PRÉSIDENT DE L'ASSEMBLÉE GÉNÉRALE
Cf. au verso (3)
I HEREBY GIVE PROXY TO THE CHAIRMAN OF THE GENERAL MEETING
See reverse (3)

JE DONNE POUVOIR À : Cf. au verso (4)
pour me représenter à l'Assemblée
I HEREBY APPOINT: See reverse (4)
to represent me at the above mentioned Meeting
M. ou Mme, Raison Sociale / Mr or Mrs, Corporate Name
Adresse / Address

ATTENTION : Pour les titres au porteur, les présentes instructions doivent être transmises à votre banque.
CAUTION: As for bearer shares, the present instructions must be valid only if they are directly returned to your bank.

Nom, prénom, adresse de l'actionnaire (les modifications de ces informations doivent être adressées à l'établissement concerné et ne peuvent être effectuées à l'aide de ce formulaire). Cf. au verso (1)
Surname, first name, address of the shareholder (changes regarding this information have to be notified to relevant institution, no changes can be made using this proxy form). See reverse (1)

1	2	3	4	5	6	7	8	9	10	A	B
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
11	12	13	14	15	16	17	18	19	20	C	D
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
21	22	23	24	25	26	27	28	29	30	E	F
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
31	32	33	34	35	36	37	38	39	40	G	H
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
41	42	43	44	45	46	47	48	49	50	J	K
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>

Si des amendements ou des résolutions nouvelles étaient présentés en assemblée, je vote NON sauf si je signale un autre choix en notifiant le cas échéant le cas échéant.
In case amendments or new resolutions are proposed during the meeting, I vote NO unless I indicate another choice by shading the corresponding box.

- Je donne pouvoir au Président de l'assemblée générale // I appoint the Chairman of the general meeting
- Je m'abstiens // I abstain from voting
- Je donne procuration [cf. au verso renvoi (4)] à M. ou Mme, Raison Sociale pour voter en mon nom
I appoint [see reverse (4)] Mr. or Mrs. Corporate Name to vote on my behalf

Pour être pris en considération, tout formulaire doit parvenir au plus tard :
To be considered, this completed form must be returned no later than:

sur 1^{ère} convocation / on 1st notification
sur 2^{ème} convocation / on 2nd notification

à la banque / to the bank
à la société / to the company

21 juin 2026 / June 21, 2026
CIC Service Assemblées 6 Avenue de Provence 75009 Paris - serviceproxy@cic.fr

* Si le formulaire est renvoyé daté et signé mais qu'aucun choix n'est coché (carte d'admission / vote par correspondance / pouvoir au président / pouvoir à mandataire), cela vaut automatiquement pouvoir au Président de l'assemblée générale.
If the form is returned dated and signed but no choice is checked (admission card / postal vote / power of attorney to the President / power of attorney to a representative), this automatically applies as a proxy to the Chairman of the General Meeting

All documents related to the Shareholder Meeting are available on www.nicox.com

For any questions regarding the Shareholder Meeting, please contact us at ag2026nicox@nicox.com

Shareholder meeting – general information

Ordinary and Extraordinary Shareholder Meeting – June 24, 2026

Registered and Bearer shareholders

Definition

	Bearer shareholder	Registered shareholder
Shareholder Identity known by the Company	<input type="checkbox"/> No*	<input checked="" type="checkbox"/> Yes
Where are the shares held?	In a securities account with a bank	In the Company's register
Management	Managed by a bank or a broker	Managed by the Company (pure registered) or a bank (administered)
Relationship with the Company	Indirect	Direct (invitations, information)

* Except in the case of an identification request made in accordance with applicable regulations

Registered shareholder

Access to the online VOTACCESS voting platform

Registered shareholders may vote online via the secure VOTACCESS platform, accessible on the dedicated website: <https://www.actionnaire.cic-marketsolutions.eu>.

Pure registered shareholders may log in using their shareholder ID and their usual username and password, which were provided by post when their share account was opened.

Administered registered shareholders may log in using the temporary access codes sent to them by post prior to the opening of the voting period.

In the event of loss or misplacement of these credentials, please use the « Forgot your access codes? » link on the dedicated website: <https://www.actionnaire.cic-marketsolutions.eu>.

You may contact CIC customer service by email at 34318@cic.fr or by phone at +33 1 53 48 80 10, Monday to Friday from 9:00 am to 6:00 pm (Paris time).

Important : Avant d'exercer votre choix, veuillez prendre connaissance des instructions situées au verso - Important : Before selecting please refer to instructions on reverse side
Quelle que soit l'option choisie, noircir comme ceci ■ la ou les cases correspondantes, dater et signer au bas du formulaire - Whichever option is used, shade box(es) like this ■, date and sign at the bottom of the form

JE DÉSIRE ASSISTER À CETTE ASSEMBLÉE et demande une carte d'admission : dater et signer au bas du formulaire // **I WISH TO ATTEND THE SHAREHOLDER'S MEETING** and request an admission card: date and sign at the bottom of the form



ASSEMBLÉE GÉNÉRALE ORDINAIRE ET EXTRAORDINAIRE
 du mercredi 24 juin 2026 à 14h30

ORDINARY AND EXTRAORDINARY GENERAL MEETING
 on Wednesday 24th June 2026 at 2.30 pm

Société anonyme au capital social de 934 554,96 euros
 Siège social : Sundesk Sophia Antipolis, Emerald Square,
 rue Evariste Galois, 06410 Biot
 403 942 642 R.C.S. Antibes

Au siège social
 Sundesk Sophia Antipolis, Emerald Square,
 rue Evariste Galois, Bâtiment C, 06410 Biot

CADRE RÉSERVÉ À LA SOCIÉTÉ - FOR COMPANY'S USE ONLY

Identifiant - Account
 Nominatif Registered
 Porteur Bearer
 Vote simple Single vote
 Vote double Double vote
 Nombre d'actions Number of shares
 Nombre de voix - Number of voting rights

<https://www.nicox.com/fr/investisseurs/investisseurs-assemblees-generales/>

<input type="checkbox"/> JE VOTE PAR CORRESPONDANCE / I VOTE BY POST Cf. au verso (2) - See reverse (2)										Sur les projets de résolutions non agréés, je vote en noircissant la case correspondant à mon choix. On the draft resolutions not approved, I cast my vote by shading the box of my choice.	
Je vote OUI à tous les projets de résolutions présentés ou agréés par le Conseil d'Administration ou le Directoire ou la Gérance, à l'EXCEPTION de ceux que je signale en noircissant comme ceci ■ l'une des cases "Non" ou "Abstention" / I vote YES all the draft resolutions approved by the Board of Directors, EXCEPT those indicated by a shaded box, like this ■, for which I vote « No » or « I abstain ».											
1	2	3	4	5	6	7	8	9	10	A	B
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
										Abs.	<input type="checkbox"/>
11	12	13	14	15	16	17	18	19	20	C	D
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
										Abs.	<input type="checkbox"/>
21	22	23	24	25	26	27	28	29	30	E	F
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
										Abs.	<input type="checkbox"/>
31	32	33	34	35	36	37	38	39	40	G	H
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
										Abs.	<input type="checkbox"/>
41	42	43	44	45	46	47	48	49	50	J	K
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
										Abs.	<input type="checkbox"/>
Si des amendements ou des résolutions nouvelles étaient présentés en assemblée, je vote NON sauf si je signale un autre choix en noircissant la case correspondante : In case amendments or new resolutions are proposed during the meeting, I vote NO unless I indicate another choice by shading the corresponding box: - Je donne pouvoir au Président de l'assemblée générale / I appoint the Chairman of the general meeting <input type="checkbox"/> - Je m'abstiens / I abstain from voting <input type="checkbox"/> - Je donne procuration [cf. au verso renvoi (4)] à M. ou Mme, Raison Sociale pour voter en mon nom <input type="checkbox"/> I appoint [see reverse (4)] Mr, or Mrs, Corporate Name to vote on my behalf <input type="checkbox"/>											

JE DONNE POUVOIR AU PRÉSIDENT DE L'ASSEMBLÉE GÉNÉRALE
 Cf. au verso (3)
I HEREBY GIVE PROXY TO THE CHAIRMAN OF THE GENERAL MEETING
 See reverse (3)

JE DONNE POUVOIR À : Cf. au verso (4) pour me représenter à l'Assemblée
I HEREBY APPOINT: See reverse (4) to represent me at the above mentioned Meeting
 M. ou Mme, Raison Sociale / Mr or Mrs, Corporate Name
 Adresse / Address

ATTENTION : Pour les titres au porteur, les présentes instructions doivent être transmises à votre banque.
CAUTION: As for bearer shares, the present instructions must be valid only if they are directly returned to your bank.

Nom, prénom, adresse de l'actionnaire (les modifications de ces informations doivent être adressées à l'établissement concerné et ne peuvent être effectuées à l'aide de ce formulaire). Cf au verso (1)
 Surname, first name, address of the shareholder (changes regarding this information have to be notified to relevant institution, no changes can be made using this proxy form). See reverse (1)

Pour être pris en considération, tout formulaire doit parvenir au plus tard :
 To be considered, this completed form must be returned no later than:

sur 1^{ère} convocation / on 1st notification sur 2^{ème} convocation / on 2nd notification

à la banque / to the bank 21 juin 2026 / June 21, 2026
 à la société / to the company CIC Service Assemblées 6 Avenue de Provence 75009 Paris - serviceproxy@cic.fr

Date & Signature

« Si le formulaire est renvoyé daté et signé mais qu'aucun choix n'est coché (carte d'admission / vote par correspondance / pouvoir au président / pouvoir à mandataire), cela vaut automatiquement pouvoir au Président de l'assemblée générale »
 'If the form is returned dated and signed but no choice is checked (admission card / postal vote / power of attorney to the President / power of attorney to a representative), this automatically applies as a proxy to the Chairman of the General Meeting'

CONDITIONS D'UTILISATION DU FORMULAIRE

<p>(1) GÉNÉRALITÉS : Il s'agit d'un formulaire unique prévu par l'article R. 225-76 du Code de Commerce qui s'applique aux assemblées générales d'actionnaires de sociétés de droit français. QUELLE QUE SOIT L'OPTION CHOISIE : Le signataire est prié d'inscrire très exactement, dans la zone réservée à cet effet, ses nom (en majuscules), prénom usuel et adresse (les modifications de ces informations doivent être adressées à l'établissement concerné et ne peuvent être effectuées à l'aide de ce formulaire). Pour les personnes morales, le signataire doit renseigner ses nom, prénom et qualité. Si le signataire n'est pas l'actionnaire (exemple : Administrateur légal, Tuteur, etc.) il doit mentionner ses nom, prénom et la qualité en laquelle il signe le formulaire de vote. Le formulaire adressé pour une assemblée vaut pour les assemblées successives convoquées avec le même ordre du jour (article R. 225-77 alinéa 3 du Code de Commerce). Les documents prévus à l'article R. 225-76 du Code de commerce sont annexés au formulaire sauf s'ils sont disponibles sur un site internet dont l'adresse est précisée au recto. Ne pas utiliser à la fois « Je vote par correspondance » et « Je donne pouvoir » (article R. 225-81 alinéa 8 du Code de Commerce). Un guide méthodologique de traitement des assemblées générales, incluant une grille de lecture de ce formulaire de vote par correspondance est disponible sur le site de France Post Marché : https://www.france-post-marche.fr/ La version française de ce document fait foi.</p>	<p>(3) POUVOIR AU PRÉSIDENT DE L'ASSEMBLÉE GÉNÉRALE Article L. 225-106 du Code de Commerce (extrait) : "Pour toute procuration d'un actionnaire sans indication de mandataire, le président de l'assemblée générale émet un vote favorable à l'adoption de projets de résolutions présentés ou agréés par le conseil d'administration ou le directeur, selon le cas, et un vote défavorable à l'adoption de tous les autres projets de résolution. Pour émettre tout autre vote, l'actionnaire doit faire choix d'un mandataire qui accepte de voter dans le sens indiqué par le mandant".</p>	<p>Cette information porte notamment sur le fait que le mandataire ou, le cas échéant, la personne pour le compte de laquelle il agit : 1° Contrôle, au sens de l'article L. 233-3, la société dont l'assemblée est appelée à se réunir ; 2° Est membre de l'organe de gestion, d'administration ou de surveillance de cette société ou d'une personne qui la contrôle au sens de l'article L. 233-3 ; 3° Est employé par cette société ou par une personne qui la contrôle au sens de l'article L. 233-3 ; 4° Est contrôlé ou exerce l'une des fonctions mentionnées au 2° ou au 3° dans une personne ou une entité contrôlée par une personne qui contrôle la société, au sens de l'article L. 233-3. Cette information est également délivrée lorsqu'il existe un lien familial entre le mandataire ou, le cas échéant, la personne pour le compte de laquelle il agit, et une personne physique placée dans l'une des situations énumérées aux 1° à 4°. Lorsqu'en cours de mandat, survient l'un des faits mentionnés aux alinéas précédents, le mandataire en informe sans délai son mandant. A défaut par ce dernier de confirmation expresse du mandat, celui-ci est caduc. La caducité du mandat est notifiée sans délai par le mandataire à la société. Les conditions d'application du présent article sont précisées par décret en Conseil d'Etat."</p>
<p>(2) VOTE PAR CORRESPONDANCE Article L. 225-107 du Code de Commerce (extrait) : "Tout actionnaire peut voter par correspondance, au moyen d'un formulaire dont les mentions sont fixées par décret en Conseil d'Etat. Les dispositions contraires des statuts sont réputées non écrites. Pour le calcul du quorum, il n'est tenu compte que des formulaires qui ont été reçus par la société avant la réunion de l'assemblée, dans les conditions de délais fixées par décret en Conseil d'Etat. Les formulaires ne donnant aucun sens de vote ou exprimant une abstention ne sont pas considérés comme des votes exprimés". La majorité requise pour l'adoption des décisions est déterminée en fonction des voix exprimées par les actionnaires présents ou représentés. Les voix exprimées ne comprennent pas celles attachées aux actions pour lesquelles l'actionnaire n'a pas pris part au vote, s'est abstenu ou a voté blanc ou nul. (articles L. 225-96 et L. 225-98 du Code de Commerce et, s'agissant des sociétés ayant adopté le statut de la société européenne, et articles 57 et 58 du Règlement du Conseil (CE) N°2157/2001 relatif au statut de la société européenne)." Si vous votez par correspondance : vous devez obligatoirement noircir la case "Je vote par correspondance" au recto. 1 - Il vous est demandé pour chaque résolution en noircissant individuellement les cases correspondantes : - soit de voter "Oui" (vote exprimé par défaut pour les projets de résolutions présentés ou agréés, en l'absence d'un autre choix); - soit de voter "Non"; - soit de voter "Abstenu". 2 - Pour le cas où des amendements aux résolutions présentées ou des résolutions nouvelles seraient déposées lors de l'assemblée, il vous est demandé d'opter entre vote contre (vote exprimé par défaut en l'absence d'un autre choix), pouvoir au président de l'assemblée générale, abstention ou pouvoir à personne dénommée en noircissant la case correspondant à votre choix.</p>	<p>(4) POUVOIR À UNE PERSONNE DÉNOMMÉE (PERSONNE PHYSIQUE OU MORALE) Article L. 225-106 du Code de Commerce (extrait) : "I - Un actionnaire peut se faire représenter par un autre actionnaire, par son conjoint ou par le partenaire avec lequel il a conclu un pacte civil de solidarité. II - Le mandat ainsi que, le cas échéant, sa révocation sont écrits et communiqués à la société. Les conditions d'application du présent alinéa sont précisées par décret en Conseil d'Etat. III - Avant chaque réunion de l'assemblée générale des actionnaires, le président du conseil d'administration ou le directeur, selon le cas, peut organiser la consultation des actionnaires mentionnées à l'article L. 225-102 afin de leur permettre de désigner un ou plusieurs mandataires pour les représenter à l'assemblée générale conformément aux dispositions du présent article. Cette consultation est obligatoire lorsque, les statuts ayant été modifiés en application de l'article L. 225-23 ou de l'article L. 225-71, l'assemblée générale ordinaire doit nommer au conseil d'administration ou au conseil de surveillance, selon le cas, un ou des salariés actionnaires ou membres des conseils de surveillance des fonds communs de placement d'entreprise détenant des actions de la société. Cette consultation est également obligatoire lorsque l'assemblée générale extraordinaire doit se prononcer sur une modification des statuts en application de l'article L. 225-23 ou de l'article L. 225-71. Les clauses contraires aux dispositions des alinéas précédents sont réputées non écrites."</p>	<p>Article L. 22-10-41 du Code de commerce : "Toute personne qui procède à une sollicitation active de mandats, en proposant directement ou indirectement à un ou plusieurs actionnaires, sous quelque forme et par quelque moyen que ce soit, de recevoir procuration pour les représenter à l'assemblée d'une société mentionnée au premier alinéa de l'article L. 22-10-39, rend publique sa politique de vote. Elle peut également rendre publiques ses intentions de vote sur les projets de résolution présentés à l'assemblée. Elle exerce alors, pour toute procuration reçue sans instructions de vote, un vote conforme aux intentions de vote ainsi rendues publiques. Les conditions d'application du présent article sont précisées par décret en Conseil d'Etat."</p> <p>Article L. 22-10-42 du Code de commerce : "Le tribunal de commerce dans le ressort duquel la société a son siège social peut, à la demande du mandant et pour une durée qui ne saurait excéder trois ans, priver le mandataire du droit de participer en cette qualité à toute assemblée de la société concernée en cas de non-respect de l'obligation d'information prévue aux troisième à septième alinéas de l'article L. 22-10-40 ou des dispositions de l'article L. 22-10-41. Le tribunal peut décider la publication de cette décision aux frais du mandataire. Le tribunal peut prononcer les mêmes sanctions à l'égard du mandataire sur demande de la société en cas de non-respect des dispositions de l'article L. 22-10-41."</p>
<p>Les informations à caractère personnel recueillies dans le cadre du présent document sont nécessaires à l'exécution de vos instructions de vote. Vous disposez d'un certain nombre de droits concernant vos données (accès, rectification, etc.). Ces droits peuvent être exercés auprès de votre teneur de compte aux coordonnées indiquées par ce dernier.</p>		

FORM TERMS AND CONDITIONS

<p>(1) GENERAL INFORMATION: This is the sole form pursuant to article R. 225-76 du Code de Commerce which is applicable to shareholders general meetings of companies incorporated under French law. WHICHEVER OPTION IS USED: The signatory should write his/her exact name and address in capital letters in the space provided e.g. a legal guardian: (Change regarding this information have to be notified to relevant institution, no change can be made using this proxy form). If the signatory is a legal entity, the signatory should indicate his/her full name and the capacity in which he is entitled to sign on the legal entity's behalf. If the signatory is not the shareholder (e.g. a legal guardian), please specify your full name and the capacity in which you are signing the proxy. The form sent for one meeting will be valid for all meetings subsequently convened with the same agenda (article R. 225-77 alinéa 3 du Code de Commerce) The documents referred to in article R. 225-76 du Code de commerce are attached to this form unless if these documents are available on a website whose address is specified on the front of this form... Please do not use both "I vote by post" and "I hereby appoint" (article R. 225-81 alinéa 8 du Code de Commerce). A guide relating to the general meetings processing, including an interpretation grid of this proxy form, is available on the France Post Marché website at: https://www.france-post-marche.fr/ The French version of this document governs; The English translation is for convenience only.</p>	<p>(3) PROXY TO THE CHAIRMAN OF THE GENERAL MEETING Article L. 225-106 du Code de Commerce (extract): "In case of any power of representation given by a shareholder without naming a proxy, the chairman of the general meeting shall issue a vote in favor of adopting a draft resolutions submitted or approved by the Board of Directors or the Management Board, as the case may be, and a vote against adopting any other draft resolutions. To issue any other vote, the shareholder must appoint a proxy who agrees to vote in the manner indicated by his principal."</p>	<p>This information relates in particular to the event that the proxy or, as the case may be, the person on behalf of whom it acts: 1° Controls, within the meaning of article L. 233-3, the company whose general meeting has to meet; 2° Is member of the management board, administration or supervisory board of the company or a person which controls it within the meaning of the article L. 233-3; 3° Is employed by the company or a person which controls it within the meaning of article L. 233-3; 4° Is controlled or carries out one of the functions mentioned with the 2° or the 3° in a person or an entity controlled by a person who controls the company, within the meaning of the article L. 233-3.</p>
<p>(2) POSTAL VOTING FORM Article L. 225-107 du Code de Commerce (extract): "Any shareholder may vote by post, using a form the wording of which shall be fixed by a decree approved by the Conseil d'Etat. Any provisions to the contrary contained in the memorandum and articles of association shall be deemed non-existent. When calculating the quorum, only forms received by the company before the meeting shall be taken into account, on conditions to be laid down by a decree approved by the Conseil d'Etat. The forms giving no voting direction or indicating abstention shall not be considered as votes cast." The majority required for the adoption of the general meeting's decisions shall be determined on the basis of the votes cast by the shareholders present or represented. The votes cast shall not include votes attaching to shares in respect of which the shareholder has not taken part in the vote or has abstained or has returned a blank or spoilt ballot paper (articles L. 225-96 and L. 225-98 du Code de Commerce and, for the companies which have adopted the statute of European company, articles 57 and 58 of the Council Regulation (EC) n°2157/2001 on the statute for a European company). If you wish to use the postal voting form, you have to shade the box on the front of this form: "I vote by post". 1 - In such event, please comply for each resolution the following instructions by shading boxes of your choice: - either vote "Yes" (in absence of choice, vote expressed by default for the approved draft resolutions), - or vote "No", - or vote "Abstention". 2 - In case of amendments or new resolutions during the general meeting, you are requested to choose between vote "No" (vote expressed by default in absence of choice), proxy to the chairman of the general meeting, "Abstention" or proxy to a mentioned person individual or legal entity by shading the appropriate box.</p>	<p>(4) PROXY TO A MENTIONED PERSON (INDIVIDUAL OR LEGAL ENTITY) Article L. 225-106 du Code de Commerce (extract): "I - A shareholder may be represented by another shareholder, by his or her spouse, or by his or her partner who he or she has entered into a civil union with. II - The proxy as well as its dismissal, as the case may be, must be written and made known to the company. A Conseil d'Etat decree specifies the implementation of the present paragraph. III - Before every general meeting, the chairman of the board of directors or the management board, as the case may be, may organise a consultation with the shareholders mentioned in article L. 225-102 to enable them to appoint one or more proxies to represent them at the meeting in accordance with the provisions of this Article. Such a consultation shall be obligatory where, following the amendment of the memorandum and articles of association pursuant to article L. 225-23 or article L. 225-71, the ordinary general meeting is required to appoint to the board of directors or the supervisory board, as the case may be, one or more shareholder employees or members of the supervisory board of the company investment funds that holds company's shares. Such a consultation shall also be obligatory where a special shareholders' meeting is required to take a decision on an amendment to the memorandum and articles of association pursuant to article L. 225-23 or article L. 225-71. Any clauses that conflict with the provisions of the preceding sub-paragraphs shall be deemed non-existent."</p>	<p>This information is also delivered when a family tie exists between the proxy or, as the case may be, the person on behalf of whom it acts, and a natural person placed in one of the situations enumerated from 1° to 4° above. When during the proxy, one of the events mentioned in the preceding subparagraphs occurs, the proxy informs without delay his constituent. Failing by the latter to confirm explicitly the proxy, this one is null and void. The termination of the proxy is notified without delay by the proxy to the company. The conditions of application of this article are determined by a Conseil d'Etat decree."</p>
<p>Article L. 22-10-41 du Code de commerce : "Any person who proceeds to an active request of proxy, while proposing directly or indirectly to one or more shareholders, under any form and by any means, to receive proxy to represent them at the general meeting of a company mentioned in the first paragraph of the article L. 22-10-39, shall release its voting policy. It can also release its voting intentions on the draft resolutions submitted to the general meeting. It exercises then, for any proxy received without voting instructions, a vote in conformity with the released voting intentions. The conditions of application of this article are determined by a Conseil d'Etat decree."</p> <p>Article L. 22-10-42 du Code de commerce : "The commercial court of which the company's head office falls under can, at the request of the constituent and for a duration which cannot exceed three years, deprive the proxy of the right to take part in this capacity to any general meeting of the relevant company in the event of non-compliance with mandatory information envisaged from the third to seventh paragraphs of article L. 22-10-40 or with the provisions of article L. 22-10-41. The court can decide the publication of this decision at the expenses of the proxy. The court can impose the same sanctions towards the proxy on request of the company in the event of non-compliance of the provisions of the article L. 22-10-41."</p> <p>Personal data included in this form are necessary for the execution of your voting instructions. You have certain minimum rights regarding your data (access, correction...). These rights may be exercised using the contact details provided by your custodian.</p>		

Translation disclaimer: This English language version of the Agenda and Summary of the draft resolutions is a free translation of the original version prepared in French for the Shareholder meeting convened on June 24, 2026. All possible care has been taken to ensure that this translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. In consequence, the translation may not be relied upon to sustain any legal claim, nor be used as the basis of any legal opinion and Nicox SA expressly disclaims all liability for any inaccuracy herein.

NICOX SA

AGENDA AND SUMMARY OF THE DRAFT RESOLUTIONS

ORDINARY AND EXTRAORDINARY SHAREHOLDER MEETING

CONVENED ON JUNE 24, 2026

Agenda of the ordinary meeting

- Approval of the 2025 annual statutory accounts (resolution 1).
- Allocation of the 2025 year-end results (resolution 2).
- Approval of Statutory Auditors' report on agreements with related parties (resolution 3).
- Acknowledgment of the resignation of Mrs. Sonia Benhamida from her position as observer (resolution 4).
- Acknowledgment of the expiration of the term of office of Approbans Audit as statutory auditor (resolution 5).
- Authorization for the Board of Directors to implement a share buyback program (resolution 6).
- Power of attorney to complete the formalities (resolution 7).

Agenda of the extraordinary meeting

- Delegation of competence to the Board of Directors to issue shares, equity securities giving right to other equity securities or debt securities and other securities giving access to newly issued equity securities of the Company, with preferential right of subscription of the shareholders (resolution 8).
- Delegation of competence to the Board of Directors to issue shares, equity securities giving right to other equity securities or debt securities and other securities giving access to newly issued equity securities, without preferential right of subscription of the shareholders and by way of public offering (other than the public offering pursuant to Article L. 411-2 1° of the French Financial and Monetary Code) (resolution 9).
- Delegation of competence to the Board of Directors to issue shares, equity securities giving right to other equity securities or debt securities and other securities giving access to newly issued equity securities, without preferential right of subscription of the shareholders and by way of a public offering pursuant to Article L 411-2 1° of the French Financial and Monetary Code (private placement) (resolution 10).

Translation disclaimer: This English language version of the Agenda and Summary of the draft resolutions is a free translation of the original version prepared in French for the Shareholder meeting convened on June 24, 2026. All possible care has been taken to ensure that this translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. In consequence, the translation may not be relied upon to sustain any legal claim, nor be used as the basis of any legal opinion and Nicox SA expressly disclaims all liability for any inaccuracy herein.

- Delegation of competence to the Board of Directors to increase the share capital for the benefit of a category of investors without preferential right of subscription of the shareholders (resolution 11).
- Authorization to the Board of Directors to increase the number of securities to be issued in the context of an issuance carried out pursuant to the fifth, sixth, seventh, eighth and tenth resolutions, with or without preferential right of subscription of the shareholders (resolution 12).
- Delegation of competence to the Board of Directors to increase the share capital by capitalization of reserves, provisions, premiums or other sums the capitalization of which would be permitted (resolution 13).
- Delegation of competence to the Board of Directors to increase the share capital in connection with a profit sharing plan reserved for the Company's employees without preferential right of subscription of the shareholders (resolution 14).
- Authorization to the Board of Directors to grant free shares, existing or to be issued, to employees and eligible corporate officers (resolution 15).
- Authorization to the Board of Directors to grant stock-options to subscribe new shares or purchase existing shares to employees and eligible corporate officers (resolution 16).
- Authorization to the Board of Directors to reduce the share capital by cancellation of previously repurchased shares in the context of a share repurchase plan (resolution 17).
- Power of attorney to complete the formalities (resolution 18).

SUMMARY OF THE RESOLUTIONS

ORDINARY PART

First resolution

Approval of the annual statutory accounts and management report for financial year ending December 31, 2025 which show a loss of €2,412,924.23.

Second resolution

Transfer of the year end loss of € 2,412,924.23 as of December 31, 2025, to the "Carried forward" account which would bring the balance to € - 533,240,978.73. No dividends will be distributed.

Translation disclaimer: This English language version of the Agenda and Summary of the draft resolutions is a free translation of the original version prepared in French for the Shareholder meeting convened on June 24, 2026. All possible care has been taken to ensure that this translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. In consequence, the translation may not be relied upon to sustain any legal claim, nor be used as the basis of any legal opinion and Nicox SA expressly disclaims all liability for any inaccuracy herein.

Third resolution

Acknowledgment of the special report of the Statutory Auditors on agreements with related parties – no related party agreement.

Fourth resolution

Acknowledgment of the resignation of Mrs. Sonia Benhamida from her position as observer and decision not to renew her appointment nor to appoint a replacement .

Fifth resolution

Acknowledgment of the expiration of the term of office of Approbans Audit as statutory auditor and decision not to replace them.

Sixth resolution

Authorization for the Board to purchase its own shares within the limit of 10% of the share capital for either of the following purposes:

- to allocate Nicox shares as a means of payment or exchange, particularly in the event of external growth opportunities;
- to provide shares to employees or corporate officers of the Company or the Group, in particular under a profit sharing plan, a stock option plan or free share plan;
- to deliver shares upon exercise of rights attached to securities giving access to Nicox' share capital;
- to reduce the share capital by cancelling all or part of the shares purchased by the Company;
- to promote liquidity through a financial service provider pursuant to a contract complying with market practice approved by the French financial markets authority (*"Autorité des Marchés Financiers"*);
- for use in the context of all operations aiming to cover the undertakings of the Company with respect to financial instruments concerning, inter alia, the evolution of the trading price of the Company's stock;
- to implement any future market practice authorized by law or by the AMF.

This resolution, which replaces the resolution voted by the 2025 shareholder meeting, is granted for a period of 18 months. The maximum unit purchase price would be €1.50

This authorization can be used in the event of take-over bid or public exchange offer on the Company's securities.

Translation disclaimer: This English language version of the Agenda and Summary of the draft resolutions is a free translation of the original version prepared in French for the Shareholder meeting convened on June 24, 2026. All possible care has been taken to ensure that this translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. In consequence, the translation may not be relied upon to sustain any legal claim, nor be used as the basis of any legal opinion and Nicox SA expressly disclaims all liability for any inaccuracy herein.

Seventh resolution

Power for legal formality requirements.

EXTRAORDINARY PART

Eighth resolution

(RIGHT ISSUES) Delegation of competence to the Board of Directors to proceed with increases in share capital (issuance of shares, equity securities giving right to other equity securities or debt securities and securities giving right to newly issued equity securities – in euro or other currencies) up to a maximum nominal amount of €2,000,000 for a period of 26 months. Under this resolution, shareholders keep their preferential rights of subscription to the newly issued securities.

This resolution includes the possibility of issuing debt securities giving right to shares up to a maximum amount €100,000,000.

(The maximum nominal amount of €1,000,000 under this resolution applies globally to all the authorizations under resolutions 8, 9, 10, 11, 12, 13 and 14)

Ninth resolution

(PUBLIC OFFERINGS) Delegation of competence to the Board of Directors to proceed with increases in share capital (issuance of shares, equity securities giving right to other equity securities or debt securities and securities giving right to newly issued equity securities – in euro or other currencies) by way of public offering (except public offerings within the meaning of Article L. 411-2 1° of the French Commercial Code), subject to the maximum nominal amount of €1,000,000 for a period of 26 months.

Under this resolution, shareholders waive their preferential rights of subscription to the newly issued securities. However, the Board of Directors may set a priority period during which the shareholders can subscribe in priority to the extent of its holding in the capital. The duration of the priority period will be set freely by the Board of Directors.

Accordingly, the price per equity security to be issued hereunder shall be equal to no less than:

- a 30 % discount on the last three trading days weighted average price (VWAP) of the Nicox share prior to the beginning of the public offering

This resolution also includes the possibility of issuing debt securities giving right to shares up to a maximum amount €100,000,000, subject to the global nominal amount of €100,000,000 provided for in resolution 8.

Translation disclaimer: This English language version of the Agenda and Summary of the draft resolutions is a free translation of the original version prepared in French for the Shareholder meeting convened on June 24, 2026. All possible care has been taken to ensure that this translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. In consequence, the translation may not be relied upon to sustain any legal claim, nor be used as the basis of any legal opinion and Nicox SA expressly disclaims all liability for any inaccuracy herein.

(The utilization of this authorization is subject to the following global amount nominal amount:

- Maximum nominal amount of €2,000,000 with the utilizations of the authorizations under resolutions 8, 9, 10, 11, 12, 13 and 14.
- Maximum nominal amount of €1,000,000 with the utilizations of the authorizations under resolutions 9, 10, 11 and 13)

Tenth resolution

(PRIVATE PLACEMENT) Delegation of competence to the Board of Directors to proceed with increases in share capital (issuance of shares, equity securities giving right to other equity securities or debt securities and securities giving right to newly issued equity securities – in euro or other currencies) by way of a private placement (qualified as a public offering within the meaning of Article L. 411-2 1° of the French Commercial Code, since the entry into force of the new EU prospectus regulation in July 2019), subject to the maximum nominal amount of €1,000,000 and a maximum of 30% of the share capital per year for a period of 26 months. Under this resolution, shareholders waive their preferential rights of subscription to the newly issued securities.

Accordingly, the price per equity security to be issued hereunder shall be equal to no less than:

- the last three trading days weighted average price (VWAP) of the Nicox share prior to the beginning of the public offering with a maximum discount of 30 %.

This resolution also includes the possibility of issuing debt securities giving right to shares up to a maximum amount €100,000,000, subject to the global nominal amount of €100,000,000 provided for in resolution 8.

(The utilization of this authorization is subject to the following global amount nominal amount:

- Maximum nominal amount of €2,000,000 with the utilizations of the authorizations under resolutions 8, 9, 10, 11, 12, 13 and 14.
- Maximum nominal amount of €1,000,000 with the utilizations of the authorizations under resolutions 9, 10, 11 and 13)

Eleventh resolution

(CATEGORIES OF PERSON/EQUITY LINES) Delegation of competence to the Board of Directors, subject to the maximum nominal amount of €1,000,000 and for a period of 18 months, to increase the share capital (issuance of shares, equity securities giving right to other equity securities or debt securities and securities giving right to newly issued equity securities), for the benefit of one or several persons which belong to the following categories:

- **(Funds or natural persons for equity lines)** one or more natural persons or legal entities, trusts, investment funds or other investment vehicles, whatever their form,

Translation disclaimer: This English language version of the Agenda and Summary of the draft resolutions is a free translation of the original version prepared in French for the Shareholder meeting convened on June 24, 2026. All possible care has been taken to ensure that this translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. In consequence, the translation may not be relied upon to sustain any legal claim, nor be used as the basis of any legal opinion and Nicox SA expressly disclaims all liability for any inaccuracy herein.

governed by French or foreign law, usually investing, or having invested more than €5 million over the 24 months preceding the capital increase in question, in the pharmaceutical and/or biotechnology sector; and/or

- **(Strategic partner)** to one or more of the Company's strategic partners, located in France or abroad, who have entered into or are due to enter into one or more commercial partnership agreements (development, co-development, distribution, manufacturing, etc.) with the Company (or a subsidiary) and/or to one or more companies that these partners control, that control these partners or that are controlled by the same person(s) as these partners, directly or indirectly, within the meaning of Article L.233-3 of the French Commercial Code;
- **(Creditors)** any person, including the Company's suppliers or bondholders, with a claim on the Company that is certain, liquid and due.

Accordingly, the price per equity security to be issued hereunder shall be equal to no less than:

- the last three trading days weighted average price (VWAP) of the Nicox share prior to the beginning of the public offering with a maximum discount of 30 %.

Under this resolution, shareholders waive their preferential rights of subscription to the newly issued securities.

This resolution also includes the possibility of issuing debt securities giving right to shares up to a maximum amount of €100,000,000, subject to the global nominal amount of €100,000,000 provided for in resolution 8.

(The utilization of this authorization is subject to the following global amount nominal amount:

- Maximum nominal amount of €2,000,000 with the utilizations of the authorizations under resolutions 8, 9, 10, 11, 12, 13 and 14,
- Maximum nominal amount of €1,000,000 with the utilizations of the authorizations under resolutions 9, 10, 11 and 13)

Twelfth resolution

(OVERALLOTMENT) Authorization to the Board of Directors, for a period of 26 months, to increase the number of securities to be issued in the context of an increase of the share capital (with or without shareholders preferential rights of subscription) under resolutions 8, 9, 10, 11 and 14 within 30 days of the end of the subscription period of the initial increase and within the limit of 15% of the amount thereof and under identical pricing conditions.

(The utilization of this authorization is subject to the following global amount nominal amount:

- Maximum nominal amount of €2,000,000 with the utilizations of the authorizations under resolutions 8, 9, 10, 11, 12, 13 and 14,
- Maximum nominal amount of €1,000,000 with the utilizations of the authorizations under resolutions 9, 10, 11 and 13)

Translation disclaimer: This English language version of the Agenda and Summary of the draft resolutions is a free translation of the original version prepared in French for the Shareholder meeting convened on June 24, 2026. All possible care has been taken to ensure that this translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. In consequence, the translation may not be relied upon to sustain any legal claim, nor be used as the basis of any legal opinion and Nicox SA expressly disclaims all liability for any inaccuracy herein.

Thirteenth resolution

Delegation of competence to the Board of Directors, for a period of 26 months, to increase the share capital by incorporation of reserves, profits, premiums or other distributable amounts subject to the amount available for incorporation.

Fourteenth resolution

Delegation of competence to the Board of Directors, for a period of 26 months, to proceed with increases in share capital up to a maximum nominal amount of €1,000,000 in connection with profit sharing plans reserved for the Company's employees and waiver of the shareholders' preferential subscription rights.

This resolution is subject to the maximum nominal amount of €2,000,000 provided for in resolution 8.

Fifteenth resolution

Authorization granted to the Board of Directors, for a period of 38 months, to grant to employees and eligible corporate officers of the Group free shares within the limit of 15% of the share capital calculated on the grant date.

The granting of the shares will be subject to the achievement of performance criteria to be fixed by the Board.

The Board may choose between two possibilities:

- the attribution of shares to the beneficiaries would only become firm at the expiry of a minimum one year period and, subsequently, the shares may not be sold before an additional minimum one year period;
- the attribution of shares to the beneficiaries would only become firm at the expiry of a minimum two year period in which case the shares may then be sold immediately.

These time limits may be extended by the Board of Directors.

(The maximum shares to be issued under the resolution 15 and 16 may not exceed 15% of the share capital calculated on the grant date.)

Sixteenth resolution

Authorization granted to the Board of Directors for a period of 38 months to grant to employees and eligible corporate officers of the group, stock options giving right to subscribe within the limit of 15% of the share capital calculated on the grant date.

The subscription price of the shares may not be:

Translation disclaimer: This English language version of the Agenda and Summary of the draft resolutions is a free translation of the original version prepared in French for the Shareholder meeting convened on June 24, 2026. All possible care has been taken to ensure that this translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions expressed therein, the original language version of the document in French takes precedence over this translation. In consequence, the translation may not be relied upon to sustain any legal claim, nor be used as the basis of any legal opinion and Nicox SA expressly disclaims all liability for any inaccuracy herein.

- less than the weighted average price of the Nicox share over the 20 trading days preceding the date of the decision of the board to grant the stock-options, it being specified that the subscription price of the shares thus determined cannot be less than the price determined in accordance with the objective methods used in share valuation, taking into account, according to a weighting appropriate to the Company, the net book value, profitability and business prospects of the Company on a consolidated basis.

(The maximum shares to be issued under the resolution 15 and 16 may not exceed 15% of the share capital calculated on the grant date.)

Seventeenth resolution

Authorization to the Board of Directors to reduce the share capital by cancelling shares that have been repurchased under the share buyback program authorized in resolution 6 up to a limit of 10% of the share capital over a 24-month period. This authorization is granted for a period of 18 months.

Eighteenth resolution

Power for legal formality requirements.

* * *

BRIEF OVERVIEW OF THE COMPANY'S SITUATION

Significant events for the year ended December 31, 2025

Execution of a financing facility agreement with Vester Finance

On March 5, 2025, the Company signed a flexible financing agreement with Vester Finance in the form of a “PACEO” capital increase program involving the exercise of warrants (*Programme d’Augmentation de Capital par Exercice d’Options* or “PACEO”) for up to 10,000,000 shares over a 24-month period. Pursuant to the terms of the agreement signed on March 5, 2025, Vester Finance committed to subscribe, at its own initiative and subject to certain customary contractual conditions, for up to 10,000,000 ordinary shares of the Company. The Company fully utilized this financing facility during the fiscal year ended December 31, 2025. Accordingly, a total of 10,000,000 shares were issued, representing 14.4% of the share capital before the transaction and 9.4% taking into account dilutive instruments. The shares were issued on the basis of the average daily market prices preceding each issuance, less a maximum discount of 6.5%, within the pricing and dilution limits set by the General Meeting of the shareholders.¹² The net proceeds from the issuance were received after deduction of a 2.5% commission. Net proceeds amounted to €2.4 million after deduction of the 2.5% commission. Use of this financing facility resulted in dilution for existing shareholders. Accordingly, a shareholder holding 1.00% of the Company’s share capital prior to implementation of the facility would see its interest reduced to 0.87% following full utilization. This transaction was decided by the Chief Executive Officer pursuant to the sub-delegation granted by the Company’s Board of Directors on March 5, 2025, itself acting under the delegation granted by the General Meeting held on May 6, 2024 under the 8th resolution.³ The transaction did not require the preparation of a prospectus subject to approval by the AMF (*Autorité des Marchés Financiers*), the French financial market authority. This equity financing facility was structured and subscribed by Vester Finance, a European company that regularly invests in growth companies (“small caps”), notably in the healthcare and biotechnology sectors. Vester Finance, acting solely as an investor with no intention of remaining a shareholder, may resell the shares within a shorter or longer timeframe.

Results of the exploratory Whistler Phase 3b glaucoma trial

On May 14, 2025, the Company announced the results of the Whistler Phase 3 exploratory clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering in healthy volunteers and ocular hypertensive patients. Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; likewise those that respond to prostaglandin analogs. Episcleral venous pressure

¹ the lowest volume-weighted average daily share price calculated over the two consecutive trading days preceding an exercise request.

² Under this delegation of authority, the issue price of the shares must be “at least equal to the average of the volume-weighted average share prices over the last three trading days preceding the determination of the issue price, potentially reduced by a maximum discount of 30%.”

³ Delegation of authority to increase the share capital with cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics.

changes did not show a trend vs. placebo. The safety profile is consistent with that of the first Phase 3 trial, Mont Blanc.

Approval to initiate Phase 3 clinical trials for NCX 470 in Japan

On May 27, 2025, the Company announced that its exclusive Japanese partner for NCX 470, Kowa, has received Clinical Trial Notification (equivalent of a U.S. Investigational New Drug, IND) approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Japan. This approval triggered a €1 million milestone payment to the Company.

Signature of a major agreement between Nicox and Kowa for up to €191.5 million relating to the exclusive rights to glaucoma treatment NCX 470 in the United States and all non-licensed territories

On July 17, 2025, the Company announced the signing of a major new agreement concerning NCX 470 with Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing. The agreement, worth up to €191.5 million, grants Kowa exclusive rights to develop and commercialize NCX 470, Nicox's nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. These rights cover the United States and all other territories of the world excluding Japan, China, Korea and Southeast Asia. Kowa already holds a license for NCX 470 in Japan, where the initiation of a Phase 3 clinical trial is in preparation.

Under the terms of the agreement, Nicox received an upfront payment of €7.5 million on signing. Following the positive results from the Denali Phase 3 clinical trial, an additional €5 million milestone payment was triggered. Additional milestone payments are expected, notably upon submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), currently anticipated in summer 2026. Total potential development and commercial milestone payments could reach either €191.5 million or €127 million, depending on the outcome of the Denali clinical trial. Following the Phase 3 results and the payments already received, remaining potential future payments now fall within the €127 million package..

In addition, Kowa will pay Nicox tiered royalties in the U.S. which could reach 20% of net sales, with the initial royalty rate depending on the results of the Denali clinical trial (8% or 10%). Outside of the U.S., Nicox will receive tiered royalties ranging from single-digit to double-digit percentages.

Initiation by Kowa of a Phase 3 clinical trial for NCX 470 in Japan

On August 5, 2025, the Company announced that its exclusive Japanese partner, Kowa, has initiated a Phase 3 safety clinical trial of NCX 470 (also known as K-911) in Japan for the treatment of ocular hypertension, triggering a €2 million milestone payment to Nicox. Only one Phase 3 confirmatory clinical trial in Japanese patients is required for submission for marketing approval of NCX 470 in Japan, in addition to this safety trial. This trial was also initiated in 2025. Kowa is responsible for financing and managing the trials under the February 2024 license agreement with Nicox.

Extension of the existing flexible financing facility with Vester Finance

On August 8, 2025, the Company announced an extension of the PACEO equity line of financing entered into with Vester Finance on March 5, 2025, with an additional maximum of 5,000,000 shares. The other

terms of the financing, as announced on March 6, 2025, remained unchanged, including the conditions and issue price of the additional shares. The Company fully utilized the extension of this financing facility during the fiscal year ended December 31, 2025. Accordingly, a total of 5,000,000 shares were issued, representing 6.4% of the share capital before the transaction and 4.3% taking into account dilutive instruments. Net proceeds from the issuance amounted to €1.5 million.

Positive results for NCX 470 in the Denali Phase 3 trial in glaucoma patients

On August 21, 2025, the Company announced that once daily dosing of NCX 470 0.1%, a novel nitric oxide (NO)-donating bimatoprost eye drop, met the primary objective of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%, in the Denali Phase 3 clinical trial involving 696 patients with open-angle glaucoma or ocular hypertension. The IOP-lowering effect from baseline for NCX 470 was 7.9 to 10.0 mmHg vs. 7.1 to 9.8 mmHg for latanoprost (reduction in time-matched IOP at 8 AM and 4 PM across the week 2, week 6 and month 3 visits). In a pre-specified secondary efficacy analysis of time-matched change from baseline IOP, the IOP reductions for NCX 470 0.1% were numerically greater than those for latanoprost at 5 of the 6 timepoints, and statistically significant ($p < 0.05$) at 3 of the 6 timepoints. However, overall statistical superiority was not achieved. These results are consistent with those of Mont Blanc, the first Phase 3 trial, successfully completed in 2022, and confirm the efficacy profile required for regulatory submissions in the U.S. and China.

NCX 470 demonstrates Sustained Efficacy through 12 Months in the Denali Clinical Trial with no new Safety Observations

On October 2, 2025, the Company announced that it had completed the additional pre-planned analyses of the NCX 470 Denali Phase 3 clinical trial data. These analyses confirm an efficacy profile similar to that seen in subgroup analysis of the Mont Blanc trial. In addition, reduction in intraocular pressure (IOP) was measured in the long-term safety extension period of the Denali trial from 6 months through to 12 months. NCX 470 maintained robust IOP reduction during this period with no additional safety signals seen.

Nicox completes NCX 470 new drug application key data generation for submission as planned in H1 2026

On December 16, 2025, the Company announced that it had successfully completed generation and analysis of all key data required to support the submission of New Drug Applications (NDAs) in the U.S. and China. Specifically, this includes all clinical trial and long-term stability data, compliant with International Council for Harmonisation (ICH) guidelines, on batches of both the NCX 470 drug material and finished drug product. In addition to data from the NCX 470 clinical trials, these other elements are a standard part of an NDA submission and support the manufacturing process and shelf life of both the active ingredient and finished product, as well as the drug metabolism study. The Company is now proceeding with the preparation of the NDA, which is being conducted at Kowa's cost.



Nicox announces the complete repayment of Kreos Capital debt

On December 31, 2025, the Company fully repaid all outstanding debt with funds and accounts managed by Kreos Capital using available cash at that date, thereby releasing all security interests over Nicox's assets and terminating Kreos Capital's right to appoint an observer to the Board of Directors. Nicox announced this repayment on January 5, 2026.

All the Company's press releases are available at <https://www.nicox.com/news-and-events/>.